Literature DB >> 2110573

Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.

D H Sarne1, S Sobieszczyk, K B Ain, S Refetoff.   

Abstract

Serum TSH and PRL levels and their response to TRH were measured in 11 patients with generalized resistance to thyroid hormone (GRTH), 6 euthyroid subjects, and 6 patients with primary hypothyroidism. TSH and PRL levels and their response to TRH were also measured after the consecutive administration of 50, 100, and 200 micrograms T3 daily, each for a period of 3 days. Using a sensitive TSH assay, all GRTH patients had TSH values that were elevated or within the normal range. On the basis of a normal or elevated TSH level, GRTH patients were classified as GRTH-N1 TSH (5 patients) or GRTH-Hi TSH (6 patients), respectively. Only GRTH patients with previous thyroid ablative therapy had basal TSH values greater than 20 mU/L. TSH responses, in terms of percent increment above baseline, were appropriate for the basal TSH level in all subjects. No GRTH patient had an elevated basal PRL level. PRL responses to TRH were significantly increased only in the hypothyroid controls compared to values in all other groups. On 50 micrograms T3, 7 of 12 (58%) nonresistant (euthyroid and hypothyroid) and 1 of 11 (9%) resistant subjects had a greater than 75% suppression of the TSH response to TRH. On the same T3 dose, 2 of 12 (17%) nonresistant and 4 of 11 (36%) resistant subjects had a greater than 50% suppression of the PRL response to TRH. On 200 micrograms T3, all subjects, except for 1 with GRTH, had a greater than 75% suppression of the TSH response to TRH. On the same T3 dose, while 11 of 12 (92%) nonresistant subjects had a greater than 50% reduction of the PRL response to TRH, only 3 of 10 (30%) resistant patients showed this degree of suppression (P less than 0.005). Without previous ablative therapy, serum TSH in patients with GRTH is usually normal or mildly elevated. The TSH response to TRH is proportional to the basal TSH level and is suppressed by exogenous T3. However, on 200 micrograms T3 basal TSH was not detectable (less than 0.1 mU/L) in all euthyroid subjects, but it was measurable in three of four GRTH patients with normal TSH levels before T3 treatment. PRL levels in GRTH are normal even when TSH is elevated. The PRL response to TRH is not increased in GRTH. In all subjects, exogenous T3 suppresses the PRL response to TRH to a lesser degree than the TSH response, but this difference is much greater in patients with GRTH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110573     DOI: 10.1210/jcem-70-5-1305

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Endocrinology.

Authors:  M A Baxter; M C Sheppard
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

2.  Variable clinical presentation and outcome in pediatric patients with resistance to thyroid hormone (RTH).

Authors:  Ana Chiesa; Maria Cecilia Olcese; Patricia Papendieck; Alicia Martinez; Ana Vieites; Sonia Bengolea; Héctor Manuel Targovnik; Carina Marcela Rivolta; Carina Maria Rivolta; Laura Gruñeiro-Papendieck
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

3.  Screening of nineteen unrelated families with generalized resistance to thyroid hormone for known point mutations in the thyroid hormone receptor beta gene and the detection of a new mutation.

Authors:  K Takeda; S Balzano; A Sakurai; L J DeGroot; S Refetoff
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

4.  A clinician's guide to understanding resistance to thyroid hormone due to receptor mutations in the TRα and TRβ isoforms.

Authors:  Brijesh K Singh; Paul M Yen
Journal:  Clin Diabetes Endocrinol       Date:  2017-09-15

5.  The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience.

Authors:  Irene Campi; Danila Covelli; Carla Moran; Laura Fugazzola; Chiara Cacciatore; Fabio Orlandi; Gabriella Gallone; Krishna Chatterjee; Paolo Beck-Peccoz; Luca Persani
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-07       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.